Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-evaluering av betingelser for aktiv overvåkingsegnethet som behandling

12. november 2026 oppdatert av: QuantumLeap Healthcare Collaborative

DCIS: RECAST-forsøk - Duktalt karsinom in situ: re-evaluering av betingelser for aktiv overvåkingsegnethet som behandling: en pilotstudie for forebygging av brystkreft

The goal of this trial is to see if active surveillance monitoring and hormonal therapy in patients diagnosed with ductal cell carcinoma in situ (DCIS), an early stage of breast cancer, can be an effective management of the disease.

Participants will be asked to receive control hormonal therapy or an investigational hormonal therapy treatment. Participants will be asked to return for evaluation with MRI at three months and six months. Depending on the evaluation participants will have the option to continue on the treatment. If the evaluation suggests surgery is recommended, the participant will discontinue the study treatment and will undergo surgery. In addition to the treatment and MRI evaluation, participants will be asked to provide blood sample to understand their immune status, provide saliva sample for genetic testing, provide the study with a portion of the tissue or slides generated from tissue removed during surgery performed as part of their standard of care.

Studieoversikt

Detaljert beskrivelse

The goal of this trial is to see if active surveillance monitoring and hormonal therapy in patients diagnosed with Ductal cell Carcinoma In Situ (DCIS), an early stage of breast cancer, can be an effective management of the disease. The current management of most patients with DCIS involves surgical intervention with or without radiation, similar to more aggressive breast cancers. These treatments can come with some significant health effects.The main question this study aims to answer is: to determine whether novel endocrine therapy increases the fraction of patients who will be suitable for long-term active surveillance.

Participants will be asked to take one of three investigational study medication (z-Elacestrant, Testosterone + Anastrazole, or Endoxifen) or receive control hormonal therapy (Tamoxifen or an aromatase inhibitor), depending on the treatment to which they have been randomized. Participants will be asked to return for evaluation with MRI at three months and six months. Depending on the evaluation, participants will have the option to continue on the treatment, with follow up evaluations of Mammogram and MRI at 6 month intervals. If the evaluation suggests surgery is recommended, the participant will discontinue the study treatment and will undergo surgery. In addition to the treatment and MRI evaluation, participants will be asked to:

  • Provide blood sample to understand their immune status
  • Provide saliva sample for genetic testing
  • Provide the study with a portion of the tissue or slides generated from tissue removed during surgery performed as part of their standard of care.

Participants will be followed annually for 10 years.

Studietype

Intervensjonell

Registrering (Antatt)

400

Fase

  • Fase 2

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

  • Navn: Tammy Neseth, MA, CCRP
  • Telefonnummer: +1 (507) 269-8060
  • E-post: t.neseth@qlhc.org

Studer Kontakt Backup

  • Navn: Sabrina Mayhew, Ph.D. Nursing
  • Telefonnummer: +1 (888) 282-7099
  • E-post: s.mayhew@qlhc.org

Studiesteder

    • California
      • Berkeley, California, Forente stater, 94158
        • Rekruttering
        • Berkeley Outpatient Center
        • Ta kontakt med:
        • Hovedetterforsker:
          • Jordan Jackson, MD
        • Ta kontakt med:
      • Duarte, California, Forente stater, 91010
        • Rekruttering
        • City of Hope -Duarte Cancer Center
        • Hovedetterforsker:
          • Jennifer Tseng, MD
        • Ta kontakt med:
          • Mellissa Henry, RN, MSN, FNP-C
          • Telefonnummer: 626-713-8895
          • E-post: mehenry@coh.org
      • Irvine, California, Forente stater, 92618
        • Rekruttering
        • City of Hope - Lennar Foundation Cancer Center
        • Hovedetterforsker:
          • Jennifer Tseng, MD
        • Ta kontakt med:
          • Mellissa Henry, RN, MSN, FNP-C
          • Telefonnummer: 626-713-8895
          • E-post: mehenry@coh.org
      • Los Angeles, California, Forente stater, 90095
        • Rekruttering
        • UCLA
        • Ta kontakt med:
        • Hovedetterforsker:
          • Mediget Teshome, MD
      • San Francisco, California, Forente stater, 94158
        • Rekruttering
        • UCSF
        • Hovedetterforsker:
          • Jordan Jackson, MD
        • Ta kontakt med:
      • South Pasadena, California, Forente stater, 91030
        • Rekruttering
        • City of Hope
        • Hovedetterforsker:
          • Jennifer Tseng, MD
        • Ta kontakt med:
          • Mellissa Henry, RN, MSN, FNP-C
          • Telefonnummer: 626-713-8895
          • E-post: mehenry@coh.org
      • Walnut Creek, California, Forente stater, 94598
        • Rekruttering
        • John Muir Health
        • Ta kontakt med:
        • Hovedetterforsker:
          • Monica Eigelberger, MD
    • District of Columbia
      • Washington D.C., District of Columbia, Forente stater, 20010
        • Rekruttering
        • MedStar Washington Hospital Center
        • Hovedetterforsker:
          • Marc Boisvert, MD
        • Ta kontakt med:
    • Florida
      • Tampa, Florida, Forente stater, 33612
        • Rekruttering
        • Moffitt Cancer Center
        • Ta kontakt med:
        • Hovedetterforsker:
          • Laura Kruper, MD
    • Georgia
      • Atlanta, Georgia, Forente stater, 30322
        • Rekruttering
        • Winship Cancer Institute, Emory University
        • Hovedetterforsker:
          • Clara Farley, MD
        • Ta kontakt med:
        • Ta kontakt med:
    • Illinois
      • Chicago, Illinois, Forente stater, 60637
    • Minnesota
      • Maple Grove, Minnesota, Forente stater, 55369
        • Rekruttering
        • Maple Grove Cancer Center
        • Ta kontakt med:
          • Oncology Access Nurse
          • Telefonnummer: 612-624-2620
          • E-post: ccinfo@umn.edu
        • Hovedetterforsker:
          • Jane Hui, MD
      • Minneapolis, Minnesota, Forente stater, 55455
        • Rekruttering
        • University of Minnesota
        • Ta kontakt med:
          • Oncology Access Nurse
          • Telefonnummer: 612-624-2620
          • E-post: ccinfo@umn.edu
        • Hovedetterforsker:
          • Jane Hui, MD
      • Minneapolis, Minnesota, Forente stater, 55404
      • Saint Louis Park, Minnesota, Forente stater, 55426
      • Saint Paul, Minnesota, Forente stater, 55101
    • New Jersey
      • Englewood, New Jersey, Forente stater, 07631
        • Rekruttering
        • Englewood Hospital and Medical Center
        • Ta kontakt med:
        • Hovedetterforsker:
          • Jennifer Marti, MD
    • New York
      • New York, New York, Forente stater, 10011
        • Rekruttering
        • Mount Sinai Chelsea
        • Hovedetterforsker:
          • Tara Balija, MD
        • Ta kontakt med:
          • Contact: Site Public Contact
          • Telefonnummer: 212-824-7309
          • E-post: CRSU@mssm.edu
      • New York, New York, Forente stater, 10029
        • Rekruttering
        • Icahn School of Medicine at Mount Sinai
        • Hovedetterforsker:
          • Tara Balija, MD
        • Ta kontakt med:
          • Contact: Site Public Contact
          • Telefonnummer: 212-824-7309
          • E-post: CRSU@mssm.edu
      • New York, New York, Forente stater, 10019
        • Rekruttering
        • Mount Sinai West
        • Hovedetterforsker:
          • Tara Balija, MD
        • Ta kontakt med:
          • Contact: Site Public Contact
          • Telefonnummer: 212-824-7309
          • E-post: CRSU@mssm.edu
      • New York, New York, Forente stater, 10003
        • Rekruttering
        • Mount Sinai Union Square
        • Hovedetterforsker:
          • Tara Balija, MD
        • Ta kontakt med:
          • Contact: Site Public Contact
          • Telefonnummer: 212-824-7309
          • E-post: CRSU@mssm.edu
      • The Bronx, New York, Forente stater, 10461
        • Rekruttering
        • Montefiore Medical Center (Hutchinson Campus Tower 1)
        • Ta kontakt med:
        • Hovedetterforsker:
          • Sheldon Feldman, MD
        • Ta kontakt med:
    • North Carolina
      • Durham, North Carolina, Forente stater, 27710
        • Rekruttering
        • Duke Cancer Institute
        • Ta kontakt med:
        • Hovedetterforsker:
          • Ton Wang, MD
      • Winston-Salem, North Carolina, Forente stater, 27157
    • Pennsylvania
      • Bryn Mawr, Pennsylvania, Forente stater, 19010
        • Aktiv, ikke rekrutterende
        • Bryn Mawr Hospital
      • Paoli, Pennsylvania, Forente stater, 19301
        • Aktiv, ikke rekrutterende
        • Paoli Hospital
      • Wynnewood, Pennsylvania, Forente stater, 19096
        • Aktiv, ikke rekrutterende
        • Lankenau Medical Center
    • Tennessee
      • Nashville, Tennessee, Forente stater, 37232
        • Rekruttering
        • Vanderbilt University Medical Center
        • Hovedetterforsker:
          • Ingrid Meszoely, MD
        • Ta kontakt med:
          • Oncology nursing
          • Telefonnummer: 1-800-811-8480
          • E-post: cip@vumc.org
        • Ta kontakt med:
    • Utah
      • Salt Lake City, Utah, Forente stater, 84112
        • Rekruttering
        • Huntsman Cancer Institute
        • Hovedetterforsker:
          • Kirstyn Brownson, MD
        • Ta kontakt med:
    • Virginia
      • Richmond, Virginia, Forente stater, 23298
        • Rekruttering
        • Virginia Commonwealth University
        • Ta kontakt med:
        • Hovedetterforsker:
          • Kandace McGuire, MD
    • Washington
      • Seattle, Washington, Forente stater, 98109
        • Rekruttering
        • Univesity of Washington (UW) / Fred Hutchinson Cancer Center (FHCC)
        • Hovedetterforsker:
          • Sara Javid, MD
        • Ta kontakt med:

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Hunn

Beskrivelse

Inclusion Criteria:

A. Female, at least 18 years old

B. Previous diagnosis of HR+ DCIS (at least 50% ER or PR; biopsy will have been performed previously at diagnosis) with or without microinvasion

  • Patients with a diagnosis of hormone positive DCIS who have undergone surgery with positive margins that have not been re-excised are candidates to enroll in the trial.

C. Patients who have previously received endocrine therapy should have a washout period of at minimum 4-6 weeks prior to the screening MRI on the RECAST-DCIS trial

D. Bilateral mammogram performed within up to 6 months (180 days) of the start of trial treatment may be used for screening evaluation. If a bilateral mammogram has been performed within 1 year (12 months) of the start of trial treatment, then a diagnostic unilateral mammogram within 6 months (180 days) of the start of trial treatment will be acceptable for screening evaluation.

E. MRI performed on an I SPY (RECAST) approved scanner within 2 months (60 days) of the start of trial treatment for lesion evaluation may be used for screening evaluation.

F. CBC w/ diff, CMP, and Lipid Panel within normal limits within a year of the start of trial treatment. Abnormal labs to be repeated within 60 days prior to the start of trial treatment. Patients will be considered eligible for screening labs that are abnormal or out-of-range if the investigator has deemed the lab results not-clinically significant

G. Negative urine or serum pregnancy test within 1 month of the start of trial treatment

H. Controlled HIV positive patients are allowed as long as their current medication does not contraindicate the study's investigational agent

I. Willingness and ability to provide tumor samples for research

Exclusion Criteria:

A. Pregnant or actively breastfeeding women

B. History of allergic reactions attributed to compounds of similar chemical or biologic composition to study agent based on review of the medical record and patient history

C. Invasive carcinoma or identification of a mass on MRI that is subsequently biopsied and found to be invasive cancer

D. Co-enrollment in clinical trials of pharmacologic agents requiring an IND

E. Ongoing treatment for DCIS other than what is specified in this protocol

F. Uncontrolled intercurrent illness, including psychiatric conditions, that would limit compliance with study requirements

G. Medical history or ongoing gastrointestinal disorders potentially affecting the absorption of investigational agent and/or tamoxifen. Active inflammatory bowel disease or chronic diarrhea, known active hepatitis A/B/C*, hepatic cirrhosis, short bowel syndrome, or any upper gastrointestinal surgery including gastric resection or banding procedures

*Active hepatitis, defined as: A (positive HA antigen or positive IgM); B (either positive HBs antigen or positive hepatitis B viral DNA test above the lower limit of detection of the assay); C (positive hepatitis C antibody result, and quantitative hepatitis C (HCV) ribonucleic acid (RNA) results greater than the lower limits of detection of the assay)

H. Participants who are unable to swallow normally or unable to take tablets and capsules. Predictable poor compliance with oral treatment

I. Participants with substantial MRI artifacts (e.g., related to localizer sequences, cardiac devices such as pacemakers, or other hardware) that render the lesion non-evaluable.

J. Severe allergy or reaction history to MRI contrast.

K. Participants currently undergoing or who have received treatment for another malignancy within the previous 6 months.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Aktiv komparator: chemoprevention therapy per investigator choice

For premenopausal women: 20 mg tamoxifen orally daily (standard dose) or 10 mg every other day (low dose).

For postmenopausal women: standard oral doses of AI of choice: exemestane 25 mg daily, letrozole 2.5 mg daily, or anastrozole 1 mg daily; or reduced exemestane dosing: 25 mg 3X per week orally.

For postmenopausal women who are not tolerating an AI, investigators can change them to the low dose (10 mg every other day) or standard dose (20 mg) of tamoxifen.

There is active follow up with MRI at baseline, 3 months, 6 months after treatment initiation, and every 6 months alternating MRI and mammogram for up to 5 years. Participants may continue treatment for up to 5 years.

For premenopausal women: 20 mg tamoxifen orally daily (standard dose) or 10 mg every other day (low dose).

For postmenopausal women who are not tolerating an AI, investigators can change them to the low dose (10 mg every other day) or standard dose (20 mg) of tamoxifen.

For postmenopausal women: standard oral doses of AI of choice: exemestane 25 mg daily, or reduced exemestane dosing: 25 mg 3 times per week orally

For postmenopausal women: standard oral doses of AI of choice: letrozole 2.5 mg daily.

For postmenopausal women: standard oral doses of AI of choice: anastrozole 1 mg daily.

Eksperimentell: Testosterone + Anastrazole (T+Ai)

White solid pellet for subcutaneous insertion consisting of 100mg Testosterone and 4mg Anastrazole, an aromatase inhibitor. A cylindrical pellet (4.5mm diameter, 6.35mm diameter) is inserted subcutaneously in the upper outer gluteal region or iliac fossa every 3 months, with treatment up to 36 months. There is active follow up with MRI at baseline, 3 months, 6 months after treatment initiation, and every 6 months alternating MRI and mammogram for up to 5 years. Participants are followed for an additional 5 years.

Investigational drug. Both pre- and post- menopausal subjects. 100mg testosterone in combination with 4mg anastrazole administered subcutaneously every 3 months for up to 3 years.

Andre navn:
  • T+Ai
Eksperimentell: Elacestrant

Selective estrogen receptor degrader, Standard dose: 400mg PO with food once daily for treatment up to 36 months. Dose reduction of Elacestrant by up to 2 dose levels permitted depending on toxicity; 400 mg to 300 mg then 300 mg to 200 mg Participants requiring more than 2 dose reductions must discontinue treatment For patients on this arm there is active follow up with MRI at baseline, 3 months, 6 months after treatment initiation, and every 6 months alternating MRI and mammogram for up to 5 years. Participants are followed by for an additional 5 years.

Investigational drug. Both pre- and post- menopausal subjects. Elacestrant 400mg PO with food once daily up to 36 months.

Eksperimentell: Endoxifen

(Z)-endoxifen is the most active metabolite of the selective estrogen receptor modulator (SERM), tamoxifen. Standard dose: 10mg PO delayed release capsule of z-endoxifen once daily for treatment up to 36 months. same time with a glass of water either 1 hour before a meal or 2 hours after a meal and should not take with alcohol. For patients on this arm there is active follow up with MRI at baseline, 3 months, 6 months after treatment initiation, and every 6 months alternating MRI and mammogram for up to 5 years. Participants are followed for an additional 5 years.

Investigational drug. Both pre- and post- menopausal subjects. (z)-endoxifen 10mg delayed release capsule 1 hour before a meal or 2 hours after a meal once daily for up to 36 months.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Patients remaining on active surveillance at 7 months
Tidsramme: 7 months

Fraction of patients remaining on active surveillance at 7 months compared to control

7 months

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
To determine whether novel endocrine therapy increases the fraction of patients who will be suitable for long-term active surveillance as measured by the fraction of patients deemed to be low-risk for invasive cancer at 6 months compared to control
Tidsramme: 6 months

Fraction of patients categorized as low risk by MRI after 6 months of treatment--Measured by cases demonstrating endocrine responsiveness (Determined based on lesion and background or lesion alone or lack of lesion and minimal background)

6 months
To determine whether novel endocrine therapy increases the fraction of patients who will be suitable for long-term active surveillance as measured by the fraction of patients deemed to be low-risk for invasive cancer at 3 months compared to control
Tidsramme: 3 months

Fraction of patients categorized as low risk by MRI after 3 months of treatment--Measured by cases demonstrating endocrine responsiveness (Determined based on lesion and background or lesion alone or lack of lesion and minimal background)

3 months
Associate rate of progression to Invasive Ductal Carcinoma (IDC) with risk categorization after 6 months of treatment at 3 years
Tidsramme: 3 years

Correlation of low-risk categorization at 6 months with subsequent rate of Invasive Ductal Cell Carcinoma progression at 3 years

3 years
To assess the QoL impact of novel endocrine therapy compared to tamoxifen or Aromatase inhibitor (Ai) at standard or low dose using PROMIS and the FACT-ES and FACT-GP5 composite score compared to control
Tidsramme: 6 months

Fraction of patients experiencing Minimum Important Difference in overall QOL measured by PROP-R statistics (PROMIS) and FACT-ES (functional assessment of cancer therapy- endocrine symptoms) and FACT-GP5, a quality of life (QoL) assessment)

6 months
For those with an identified lesion on MRI imaging, determine whether neoadjuvant endocrine therapy decreases lesion volume (qualitative, quantitative) and whether that corresponds to the biologic type of Ductal cell carcinoma In Situ (DCIS)
Tidsramme: 6 months

Rate of reduction in focal lesions (mass and non-mass enhancement (NME) at 6 months and Rate of reduction in focal lesions using automated Functional Tumor Volume

6 months
To determine whether neoadjuvant endocrine therapy decreases automated background parenchymal enhancement (BPE and automated MRI density compared to Ai and Tamoxifen
Tidsramme: 6 months

% with contralateral reduction in qualitative and automated BPE and % reduction in contralateral breast density

6 months
Determine adherence to active surveillance protocol
Tidsramme: 5 years

Time to discontinuation of therapy (Tolerability of therapy) will be measured, and Adherence rates on each regimen, as well as PROP-R, FACT-ES and FACT-GP5 score on each regimen will be measured. These assessments will be combined to evaluate efficacy and toxicity using a novel clinical benefit index.

5 years
Change in artificial intelligence predicted risk based on mammography
Tidsramme: 5 years

Correlation of BPE change with agent and compare to quantitative imaging density

5 years

Andre resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Assess Germ Line polygenic risk: assess correlation of detectable mutations with endocrine response and qualification for active surveillance at 7 months
Tidsramme: 7 months

evaluate influence of polygenic risk on endocrine response and suitability for Active Surveillance

7 months
To evaluate outcomes stratified by immune and molecular subtype based upon multiplex immuno histochemistry (IHC) clustering analysis, and RPS expression array profiling
Tidsramme: 7 months

Response stratified by multiplex immune staining for Human Epidermal growth factor receptor-2 (HER2) isoforms and Response Predictive Subtypes (RPS)

7 months

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Hovedetterforsker: Laura Esserman, MD, MBA, University of California, San Fancisco - Department of Surgery
  • Hovedetterforsker: (Co-PI) Kelly Hewitt, MD, FACS, Huntsman Cancer Institute at the University of Utah

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

17. februar 2024

Primær fullføring (Antatt)

1. november 2028

Studiet fullført (Antatt)

1. november 2033

Datoer for studieregistrering

Først innsendt

22. september 2023

Først innsendt som oppfylte QC-kriteriene

4. oktober 2023

Først lagt ut (Faktiske)

10. oktober 2023

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

17. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

12. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere